ZymoGenetics filed a lawsuit against Bristol-Myers Squibb in a US district court, alleging infringement on patents related to its fusion protein technology. In the suit, ZymoGenetics said it is seeking injunctive relief, as well as damages.
ZymoGenetics did not reveal further details about the lawsuit, but noted in a statement that the technology has previously been licensed by both Amgen and Regeneron.
Bristol-Myers Squibb spokesman Tony Plohoros commented that his company is "aware of the lawsuit; we are reviewing it as well as our legal options," Bloomberg reports.
To read more Top Story articles, click here.